Efficacy of the Administration of Melatonin 5mg in the Prevention of Delirium in Older Adults Hospitalized in the Emergency Department

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

145 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-10

Study Completion Date

2020-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the efficacy of melatonin 5mg in the prevention of Delirium in the older adults in emergency department. Half of the participants will receive melatonin 5mg and the other half will use a starch-based placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Delirium in Intensive Care by Melatonin

NCT03524937

Mechanically Ventilated Patients

COMPLETED PHASE2/PHASE3

Melatonin for Treatment of Delirium in Critically Ill Adult Patients

NCT05713877

Delirium

RECRUITING PHASE2

Melatonin Supplementation for Delirium Prevention in Acutely Hospitalized Elderly

NCT00873379

Delirium

COMPLETED PHASE3

Melatonin Use in the Intensive Care Elderly Population

NCT03013790

Delirium Melatonin

UNKNOWN PHASE4

Melatonin for Prevention of Delirium in Critically Ill Patients

NCT02615340

Delirium

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Melatonia is useful for the treatment of sleep disorders due to the interruption of the circadian rhythm, secondary to alterations caused by the environment. The doses of 5 to 10mg oral or sublingual can improve the quality of the sleep-wake cycle and alertness in short-term use.

Mechanism of action of melatonin are:

1. Binding to membrane receptors: MT1 and MT2 coupled to G protein
2. \- Union to nuclear receptors.
3. \- Interaction with cytosolic proteins.
4. \- Antioxidant of direct and indirect action.
5. \- Interaction with mitochondria.

Melatonin circulates 80% bound to albumin and the rest in free form in plasma, 85-90% is metabolized by 6-hydroxymelatonin in the liver, which is then conjugated with sulfuric acid (70-80%) or glucuronic ( 5-3%), and is excreted in urine and feces.

Melatonin and its metabolites act as catalytic antioxidants to safeguard mitochondrial electron transfer reactions, therefore, increases the efficiency of energy metabolism. Melatonin synthesis decreases significantly as age progresses and changes in the circadian cycle have been associated with accelerated aging.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Delirium in Old Age

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel Assignament

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Melatonin 5mg

Melatonin 5mg, every 24 hours for 14 days

Group Type EXPERIMENTAL

Melatonin 5 mg

Intervention Type DRUG

Placebo

Starch based placebo, every 24 hours for 14 days

Group Type PLACEBO_COMPARATOR

Melatonin 5 mg

Intervention Type DRUG

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Melatonin 5 mg

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cronocaps

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women over 60 who enter the emergency department with a stay in the ward for more than 8 hours and who will remain hospitalized for more than 48 hours due to admission pathology.
* Patients who agree to participate in the study by signing an informed consent (Signature by patient and / or family member).

Exclusion Criteria

* Patients with a history of dementia or previous neurological diseases.
* Patients with a history of psychiatric disorder.
* Patients diagnosed with any type of liver disease.
* Warfarin treatment.
* Delirium data on admission to the emergency department.
* Patients under invasive mechanical ventilation and sedation.

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No